DK2891494T3 - Fremgangsmåde til administration af hypnotisserende/beroligende midler - Google Patents
Fremgangsmåde til administration af hypnotisserende/beroligende midler Download PDFInfo
- Publication number
- DK2891494T3 DK2891494T3 DK13832739.0T DK13832739T DK2891494T3 DK 2891494 T3 DK2891494 T3 DK 2891494T3 DK 13832739 T DK13832739 T DK 13832739T DK 2891494 T3 DK2891494 T3 DK 2891494T3
- Authority
- DK
- Denmark
- Prior art keywords
- hypnotic
- administration
- procedure
- sedative agents
- sedative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012192081 | 2012-08-31 | ||
| PCT/JP2013/073414 WO2014034890A1 (ja) | 2012-08-31 | 2013-08-30 | 催眠鎮静剤の投与方式 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2891494T3 true DK2891494T3 (da) | 2023-10-23 |
Family
ID=50183693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13832739.0T DK2891494T3 (da) | 2012-08-31 | 2013-08-30 | Fremgangsmåde til administration af hypnotisserende/beroligende midler |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20150224114A1 (da) |
| EP (1) | EP2891494B1 (da) |
| JP (1) | JP6199869B2 (da) |
| KR (1) | KR102228598B1 (da) |
| CN (1) | CN104768557A (da) |
| AP (1) | AP2015008287A0 (da) |
| AU (1) | AU2013309860B2 (da) |
| BR (1) | BR112015004477A8 (da) |
| CA (1) | CA2883667A1 (da) |
| CL (1) | CL2015000494A1 (da) |
| DK (1) | DK2891494T3 (da) |
| EA (1) | EA027370B1 (da) |
| ES (1) | ES2959499T3 (da) |
| FI (1) | FI2891494T3 (da) |
| GE (1) | GEP201706755B (da) |
| HR (1) | HRP20231302T1 (da) |
| HU (1) | HUE063967T2 (da) |
| IL (1) | IL237373B (da) |
| LT (1) | LT2891494T (da) |
| MA (1) | MA37954A1 (da) |
| MX (1) | MX2015002467A (da) |
| MY (1) | MY171592A (da) |
| NZ (1) | NZ705177A (da) |
| PE (1) | PE20151374A1 (da) |
| PH (1) | PH12015500381B1 (da) |
| PL (1) | PL2891494T3 (da) |
| PT (1) | PT2891494T (da) |
| SG (1) | SG11201501358SA (da) |
| SI (1) | SI2891494T1 (da) |
| TN (1) | TN2015000067A1 (da) |
| UA (1) | UA116452C2 (da) |
| WO (1) | WO2014034890A1 (da) |
| ZA (1) | ZA201501207B (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2470935C2 (ru) | 2006-07-10 | 2012-12-27 | ПАЙОН ЮКей ЛИМИТЕД | Бензодиазепиновые соли кратковременного действия и их полиморфные формы |
| EP2305647A1 (en) | 2009-09-18 | 2011-04-06 | PAION UK Limited | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process |
| EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
| AR094963A1 (es) | 2013-03-04 | 2015-09-09 | Ono Pharmaceutical Co | Reacción de oxidación excelente en el índice de conversión |
| ES2751627T3 (es) * | 2014-07-23 | 2020-04-01 | Jiangsu Nhwaluokang Pharmaceutical Res And Development Co Ltd | Nuevo derivado de benzodiazepina y uso del mismo |
| CN105130996B (zh) * | 2015-08-07 | 2017-05-03 | 成都倍特药业有限公司 | 苯并二氮杂*衍生物的1,5‑萘二磺酸盐及晶型和它们的制备方法 |
| CN110511224A (zh) * | 2016-04-08 | 2019-11-29 | 四川科伦药物研究院有限公司 | 苯并二氮杂*衍生物的盐及其晶体形式、制备方法和用途 |
| ES3027652T3 (en) * | 2016-04-14 | 2025-06-16 | Paion Uk Ltd | Orally inhaled and nasal benzodiazepines |
| CN108503644B (zh) * | 2016-12-09 | 2019-06-14 | 成都倍特药业有限公司 | 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途 |
| CN108033964B (zh) * | 2017-12-28 | 2021-02-09 | 杭州奥默医药股份有限公司 | 一种吡啶基咪唑并苯并二氮杂卓丙酸酯化合物及其合成和应用 |
| EP3714884A1 (en) | 2019-03-27 | 2020-09-30 | Paion UK Limited | Medical uses for benzodiazepines with a particular eeg pattern |
| ES2803099B2 (es) * | 2019-07-22 | 2021-11-08 | Moehs Iberica Sl | Procedimiento de obtención de besilato de remimazolam amorfo |
| CN114478535B (zh) * | 2020-10-23 | 2024-02-09 | 成都苑东生物制药股份有限公司 | 一种苯磺酸瑞马唑仑ii晶型的制备方法 |
| JP7608179B2 (ja) * | 2021-01-12 | 2025-01-06 | 日本光電工業株式会社 | 生体情報処理装置、生体情報処理方法、プログラム及び記憶媒体 |
| CN114588164B (zh) * | 2022-04-19 | 2023-08-11 | 天津医科大学总医院 | 瑞马唑仑在预防围术期低体温和寒战中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9911152D0 (en) * | 1999-05-14 | 1999-07-14 | Glaxo Group Ltd | Short-acting benzodiazepines |
| RU2470935C2 (ru) | 2006-07-10 | 2012-12-27 | ПАЙОН ЮКей ЛИМИТЕД | Бензодиазепиновые соли кратковременного действия и их полиморфные формы |
| GB0613693D0 (en) | 2006-07-10 | 2006-08-16 | Cenes Ltd | Benzodiazepine salts (3) |
| EP2305647A1 (en) | 2009-09-18 | 2011-04-06 | PAION UK Limited | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process |
| EP2450039A1 (en) * | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
-
2013
- 2013-08-30 EP EP13832739.0A patent/EP2891494B1/en active Active
- 2013-08-30 EA EA201590467A patent/EA027370B1/ru unknown
- 2013-08-30 MA MA37954A patent/MA37954A1/fr unknown
- 2013-08-30 MX MX2015002467A patent/MX2015002467A/es unknown
- 2013-08-30 HU HUE13832739A patent/HUE063967T2/hu unknown
- 2013-08-30 PL PL13832739.0T patent/PL2891494T3/pl unknown
- 2013-08-30 PE PE2015000261A patent/PE20151374A1/es not_active Application Discontinuation
- 2013-08-30 DK DK13832739.0T patent/DK2891494T3/da active
- 2013-08-30 MY MYPI2015700589A patent/MY171592A/en unknown
- 2013-08-30 KR KR1020157007319A patent/KR102228598B1/ko active Active
- 2013-08-30 CN CN201380050548.0A patent/CN104768557A/zh active Pending
- 2013-08-30 LT LTEPPCT/JP2013/073414T patent/LT2891494T/lt unknown
- 2013-08-30 HR HRP20231302TT patent/HRP20231302T1/hr unknown
- 2013-08-30 CA CA2883667A patent/CA2883667A1/en not_active Abandoned
- 2013-08-30 NZ NZ705177A patent/NZ705177A/en unknown
- 2013-08-30 GE GEAP201313771A patent/GEP201706755B/en unknown
- 2013-08-30 SI SI201332061T patent/SI2891494T1/sl unknown
- 2013-08-30 AP AP2015008287A patent/AP2015008287A0/xx unknown
- 2013-08-30 SG SG11201501358SA patent/SG11201501358SA/en unknown
- 2013-08-30 JP JP2014533131A patent/JP6199869B2/ja active Active
- 2013-08-30 BR BR112015004477A patent/BR112015004477A8/pt not_active Application Discontinuation
- 2013-08-30 WO PCT/JP2013/073414 patent/WO2014034890A1/ja not_active Ceased
- 2013-08-30 AU AU2013309860A patent/AU2013309860B2/en active Active
- 2013-08-30 ES ES13832739T patent/ES2959499T3/es active Active
- 2013-08-30 US US14/424,340 patent/US20150224114A1/en not_active Abandoned
- 2013-08-30 PT PT138327390T patent/PT2891494T/pt unknown
- 2013-08-30 UA UAA201502945A patent/UA116452C2/uk unknown
- 2013-08-30 FI FIEP13832739.0T patent/FI2891494T3/fi active
-
2015
- 2015-02-20 PH PH12015500381A patent/PH12015500381B1/en unknown
- 2015-02-23 ZA ZA2015/01207A patent/ZA201501207B/en unknown
- 2015-02-23 TN TNP2015000067A patent/TN2015000067A1/fr unknown
- 2015-02-23 IL IL237373A patent/IL237373B/en active IP Right Grant
- 2015-02-27 CL CL2015000494A patent/CL2015000494A1/es unknown
-
2022
- 2022-02-07 US US17/665,662 patent/US20220152045A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2891494T3 (da) | Fremgangsmåde til administration af hypnotisserende/beroligende midler | |
| DK3669913T3 (da) | Anordning til indgivelse af lægemidler | |
| DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
| DK3415139T3 (da) | Administration af benzodiazepin | |
| DK3527241T3 (da) | Indretning til administration af lægemiddel | |
| DK2968529T3 (da) | Fremstilling af jordnøddeformuleringer til oral desensibilisering | |
| DK3725778T3 (da) | Formuleringer af enzalutamid | |
| DK2911623T3 (da) | Oftalmisk system til langvarig frigivelse af lægemiddel til øjet | |
| DK3023100T3 (da) | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer | |
| SI2858671T1 (sl) | Formulacija protiteles | |
| EP2648520A4 (en) | DEXMEDETOMIDINVORMISCHUNGSFORMULIERUNG | |
| DK2895156T3 (da) | Fremgangsmåde til fremstilling af terapeutiske nanopartikler | |
| DK2968221T3 (da) | Farmaceutisk sammensætning af s-ketaminhydrochlorid | |
| EP2925325A4 (en) | STABILIZED FORMULATION OF PEMETREXED | |
| EP2900411A4 (en) | QUICK RELEASE | |
| DK2827862T3 (da) | Formuleringer af bendamustin | |
| DK2740032T3 (da) | Administration af softwaredistribution til regulatorisk overensstemmelse | |
| DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner | |
| DK2836460T3 (da) | Fremgangsmåde til fremstilling af graphen | |
| DK2822965T3 (da) | FREMGANGSMÅDE TIL BERIGELSE AF IgA | |
| DK2925338T3 (da) | Frysetørret formulering af tat-nr2b9c | |
| EP2919777A4 (en) | TRANSMUCOSAL ADMINISTRATION OF TOCOTRIENOL | |
| DK2948134T3 (da) | Sammensætninger til transdermal indgivelse af mtor-inhibitorer | |
| CO6862154A2 (es) | Metabolitos de trans-clomifeno y usos de los mismos | |
| DK2981258T3 (da) | Farmaceutiske formuleringer til subkutan indgivelse af furosemid |